Other languages Omega Therapeutics, Inc.

Equities

OMGA

US68217N1054

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
2.11 ^USD	-0.94%		-3.65%	-29.90%

May. 06	Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Omega Therapeutics CFO Joshua Reed to Depart	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06
Omega Therapeutics, Inc. Designates Barbara Chan as Principal Accounting Officer, Effective as of May 31, 2024	Apr. 16
Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control	Apr. 09
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss	Mar. 28
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Omega Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28
Omega Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Novel Therapeutic for Obesity Management	Jan. 05
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 04
Top Midday Gainers	Jan. 04
Novo Nordisk Collaborates With Omega Therapeutics, Cellarity on Cardiometabolic Diseases Research	Jan. 04
Top Premarket Gainers	Jan. 04
Wegovy maker Novo Nordisk enters research tie-ups with US biotech firms	Jan. 04
Novo Nordisk Signs Research Deals With Omega Therapeutics, Cellarity	Jan. 04
Novo Nordisk : accords de recherche avec Omega et Cellarity	Jan. 04
Novo Nordisk signe des partenariats de recherche avec des biotechs américaines	Jan. 04
Omega Therapeutics, Inc. Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis	Nov. 13
Omega Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Omega Therapeutics, Inc. Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC	23-10-16
Omega Therapeutics Study of OTX-2002 Shows High Engagement With Patients, Without Dose-Limiting Toxicities	23-09-26
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO I Trial	23-09-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Omega Therapeutics, Inc.

Equities

OMGA

US68217N1054

Other languages

Filters